This review evaluates the diagnostic value of multiparametric MRI (mpMRI) and prostate-specific membrane antigen-targeted PET/CT (PSMA-targeted PET/CT) for restaging radiorecurrent prostate cancer.<h4>Methods</h4>A narrative review was conducted using PubMed and Scopus. Here, FOLH1 is linked to prostate cancer.